Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

Johann de Bono, Ramesh K. Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren Averett Byers, Zev A. Wainberg

Research output: Contribution to journal › Article › peer-review

194 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers'. Together they form a unique fingerprint.

Medicine & Life Sciences